An hydrogel comprising chitosan and two weak bases having different pKb values. In some embodiments, one of the weak bases if sodium hydrogen carbonate (SHC). Also, use of the hydrogel in medical and cosmetic treatments.

An hydrogel comprising chitosan and two weak bases having different pKb values. In some embodiments, one of the weak bases if sodium hydrogen carbonate (SHC). Also, use of the hydrogel in medical and cosmetic treatments.

A method of manufacturing a resorbable, macroporous bioactive glass scaffold comprising approximately 15-45% CaO, 30-70% SiO.sub.2, 0-25% Na.sub.2O, 0-17% P.sub.2O.sub.5, 0-10% MgO and 0-5% CaF.sub.2 by mass percent, produced by mixing with pore forming agents and specified heat treatments.

A method of manufacturing a resorbable, macroporous bioactive glass scaffold comprising approximately 15-45% CaO, 30-70% SiO.sub.2, 0-25% Na.sub.2O, 0-17% P.sub.2O.sub.5, 0-10% MgO and 0-5% CaF.sub.2 by mass percent, produced by mixing with pore forming agents and specified heat treatments.

The present description relates to a polymer composition for use in repairing tissue of a patient comprising at least one blood component, as polymer, such a chitosan, and at least one inorganic salt, such as NaCl, method of the composition and method of preparing the composition.

The present description relates to a polymer composition for use in repairing tissue of a patient comprising at least one blood component, as polymer, such a chitosan, and at least one inorganic salt, such as NaCl, method of the composition and method of preparing the composition.

Isolated heparin or heparan sulphate oligosaccharide fragments having a chain length of at least 10 saccharides and no more than 50 saccharides, which are capable of binding BMP2, are disclosed. Also disclosed is the use of the same heparin or heparan sulphate oligosaccharide fragments in kits and pharmaceutical compositions, and the use of the same heparan sulphate oligosaccharide fragments in the repair and/or regeneration of connective tissue and bones, and the treatment of wounds.

Isolated heparin or heparan sulphate oligosaccharide fragments having a chain length of at least 10 saccharides and no more than 50 saccharides, which are capable of binding BMP2, are disclosed. Also disclosed is the use of the same heparin or heparan sulphate oligosaccharide fragments in kits and pharmaceutical compositions, and the use of the same heparan sulphate oligosaccharide fragments in the repair and/or regeneration of connective tissue and bones, and the treatment of wounds.

Enzymatically degradable compositions containing biocompatible polymers reactive with glycosaminoglycan compositions having a first glycosaminoglycan compound having a first degree of acetylation and a second glycosaminoglycan compound having a second degree acetylation different than the first degree of acetylation.

Enzymatically degradable compositions containing biocompatible polymers reactive with glycosaminoglycan compositions having a first glycosaminoglycan compound having a first degree of acetylation and a second glycosaminoglycan compound having a second degree acetylation different than the first degree of acetylation.